Our Management Team
Elaine Warburton OBE | Chief Executive Officer
An experienced Board Director and entrepreneur with over 25 years' experience in biotech and healthcare/hospital management; multiple start-ups; raising angel, grant and VC investment and an authority in introducing innovative technologies into mainstream medicine.
Prof Sir John Burn | Chief Medical Officer
Prof Sir John Burn Professor of Clinical Genetics, Newcastle University; honorary consultant, Newcastle Hospitals NHS Trust; Genetics lead, UK National Institute of Health Research. Scientific advisor, Genome England. Former member Human Genetics Commission, President European Society of Human Genetics, Chair British Society for Genetic Medicine.
Jonathan O'Halloran | Chief Scientific Officer
Inventor of QMDx's proprietary nucleic acid preparation, amplification, detection and sequencing technologies with over 15 years' experience in scientific research and biotechnology, clinical laboratories and clinical management.
Julian Warburton | Chief Finance Officer
Finance with over 25 years' experience in Corporate Finance, Banking and Treasury Risk Management for FTSE 100 companies ranging from international banks, fund management, beverages, industrial, pharmaceutical, insurance, product testing and certification.
Sam Whitehouse | Chief Operating Officer
Over 10 years' biotech and medical devices experience including industrial research, managing a large portfolio of academic-industry biotech collaborations and managing UK government grant portfolios. Synthetic and surface chemist specialist.
Paul J. Fitzpatrick | President, QuantuMDx USA
25 years' entrepreneurial experience – healthcare services, medical devices; 15 years C-Level leadership; multiple startups, early stage, small to mid-size growth companies, roll-ups, turnarounds, 20 M&A transactions; has participated in raising over $30 million in private equity and VC financings.
The company engages with a large number of independent scientific, medical and commercial advisors to support every aspect of its operations. The company's technology has been extensively peer reviewed.